BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34023185)

  • 61. Hypofractionation with no boost after breast conservation in early-stage breast cancer patients.
    Arcadipane F; Franco P; De Colle C; Rondi N; Di Muzio J; Pelle E; Martini S; Ala A; Airoldi M; Donadio M; De Sanctis C; Castellano I; Ragona R; Ricardi U
    Med Oncol; 2016 Oct; 33(10):108. PubMed ID: 27573380
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy.
    Freedman G; Fowble B; Hanlon A; Nicolaou N; Fein D; Hoffman J; Sigurdson E; Boraas M; Goldstein L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1005-15. PubMed ID: 10421533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations.
    Reitsamer R; Sedlmayer F; Kopp M; Kametriser G; Menzel C; Deutschmann H; Nairz O; Hitzl W; Peintinger F
    Int J Cancer; 2006 Jun; 118(11):2882-7. PubMed ID: 16381011
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
    Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
    Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Local recurrence risk after previous salvage mastectomy.
    Tanabe M; Iwase T; Okumura Y; Yoshida A; Masuda N; Nakatsukasa K; Shien T; Tanaka S; Komoike Y; Taguchi T; Arima N; Nishimura R; Inaji H; Ishitobi M;
    Eur J Surg Oncol; 2016 Jul; 42(7):980-5. PubMed ID: 27055945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumour bed boost radiotherapy for women after breast-conserving surgery.
    Kindts I; Laenen A; Depuydt T; Weltens C
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011987. PubMed ID: 29105051
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acute toxicity and 2-year adverse effects of 30 Gy in five fractions over 15 days to whole breast after local excision of early breast cancer.
    Martin S; Mannino M; Rostom A; Tait D; Donovan E; Eagle S; Haviland J; Yarnold J
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):502-5. PubMed ID: 18556186
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cosmesis, late sequelae and local control after breast-conserving therapy: influence of type of tumour bed boost and adjuvant chemotherapy.
    Budrukkar AN; Sarin R; Shrivastava SK; Deshpande DD; Dinshaw KA
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):596-603. PubMed ID: 17706403
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Surgical management of ipsilateral breast tumor recurrence.
    Kolben T; Schwarz TM; Goess C; Blume C; Degenhardt T; Engel J; Wuerstlein R; Ditsch N; Harbeck N; Kahlert S
    Int J Surg; 2015 Nov; 23(Pt A):141-6. PubMed ID: 26449651
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ.
    Wilkinson JB; Vicini FA; Shah C; Shaitelman S; Jawad MS; Ye H; Kestin LL; Goldstein NS; Martinez AA; Benitez P; Chen PY
    Ann Surg Oncol; 2012 Nov; 19(12):3785-91. PubMed ID: 22644510
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
    Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
    [No Abstract]   [Full Text] [Related]  

  • 74. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
    Dong J; Yang Y; Han D; Zhao Q; Liu C; Sun H; Wang Z; Lin H; Huang W
    Technol Cancer Res Treat; 2021; 20():15330338211064719. PubMed ID: 34898315
    [No Abstract]   [Full Text] [Related]  

  • 75. Hypofractionated whole-breast radiotherapy and concomitant boost after breast conservation in elderly patients.
    Cante D; Franco P; Sciacero P; Girelli G; Pasquino M; Casanova Borca V; Tofani S; Porta MR; Ricardi U
    Tumori; 2016; 102(2):196-202. PubMed ID: 26350199
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of treatment interruptions in the postoperative irradiation of breast cancer.
    Bese NS; Sut PA; Ober A
    Oncology; 2005; 69(3):214-23. PubMed ID: 16127290
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
    Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
    JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience.
    Keller LM; Sopka DM; Li T; Klayton T; Li J; Anderson PR; Bleicher RJ; Sigurdson ER; Freedman GM
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):881-7. PubMed ID: 22909414
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Second breast-conserving surgery and interstitial brachytherapy vs. salvage mastectomy for the treatment of local recurrences: 5-year results.
    Smanykó V; Mészáros N; Újhelyi M; Fröhlich G; Stelczer G; Major T; Mátrai Z; Polgár C
    Brachytherapy; 2019; 18(3):411-419. PubMed ID: 30890318
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward.
    Krug D; Baumann R; Combs SE; Duma MN; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Hehr T; Piroth MD; Sedlmayer F; Souchon R; Strnad V; Budach W;
    Strahlenther Onkol; 2021 Apr; 197(4):269-280. PubMed ID: 33507331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.